5月19日 - ** 药物开发商Relay Therapeutics（RLAY.O）的股价在盘前交易中上涨11.3%，至13.37美元
** RLAY 表示， (link) 其实验性疗法 zovegalisib 在一项中期研究中显示，可缩小血管畸形并改善罕见血管疾病患者的症状
** 在12周时，约60%的患者病灶大小缩小了至少20%
** 该公司表示，截至数据截止日，几乎所有患者的病灶大小均有所缩小，且仍在接受治疗
** 血管畸形是一种罕见疾病，表现为血液或淋巴管异常生长，从而引发疼痛、肿胀及其他并发症
** 截至上一交易日收盘，RLAY今年以来累计上涨43%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.